Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glecaprevir/Pibrentasvir for HCV-Negative Recipients of HCV-Positive Kidneys
NCT03781726Phase 4Completed
- Start
- Apr 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of glecaprevir + pibrentasvir in hepatitis C (HCV). Primary endpoint: Number of Participants With Undetectable HCV. Started Apr 2019; status: completed.
02
Drugs
glecaprevir + pibrentasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03781726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03781726.